Last reviewed · How we verify
Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years Old — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Rabeprazole 40 mg | rabeprazole-40-mg | Pfizer | Proton Pump Inhibitor | H+/K+ ATPase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years Old
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years Old:
- Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years Old treatment updates — RSS
- Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years Old treatment updates — Atom
- Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years Old treatment updates — JSON
Cite this brief
Drug Landscape (2026). Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years Old — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gastroesophageal-reflux-disease-gerd-in-pediatric-patients-1-to-11-years-old. Accessed 2026-06-10.
Related
- Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years Old full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing